Trial Profile

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zurletrectinib (Primary)
Indications CNS cancer; Solid tumours; Tumours
Focus Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

11 Sep 2025 Planned number of patients changed from 55 to 70.
11 Sep 2025 Planned primary completion date changed from 25 Dec 2026 to 25 Dec 2027.
02 Jun 2025 Result (n=49) presented in the InnoCare Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com